You might also be interested in:

THOMAS SABO collections radiate a paradisiacal variety of colours from 2019

Lauf/Pegnitz (ots) - - Cross reference: Picture is available at - ...

Edel-Optics offers unique Motorsport experience at Race Of Champions 2019

Hamburg (ots) - The multichannel optician will be the official partner of the motorsport event Race Of ...

Alexander Hitzinger new Member of the Board of Management for Technical Development at Volkswagen Commercial Vehicles

Hannover (ots) - Hitzinger is additionally set to take charge of establishing and managing the 'Centre for ...

23.05.2005 – 16:00

Curasan AG

euro adhoc: curasan AG
Restructuring & Recapitalisations
curasan AG: increase in capital

---------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. ---------------------------------------------------------------------


Kleinostheim, May 23, 2005 - curasan AG (WKN 549 453), a company specialising in regenerative medicine, has today placed 250,000 new ordinary shares, in the form of bearer shares, as part of an increase in capital decided upon by the Management Board on April 20, 2005, and authorised by the Supervisory Board on April 25, 2005. The capital increase of up to EUR 250,000, from currently EUR 5,000,000 to a maximum of EUR 5,250,000, was executed within the framework of existing Authorised Capital (so-called "Genehmigtes Kapital"). The subscription right of shareholders does not apply. The issue price of the new shares is EUR 1.91 per share. The new shares shall be entitled to dividends effective from January 1, 2005.

About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. curasan AG's main goal is to occupy a leading position as a global specialist in Regenerative Medicine. For further information, please visit curasan’s corporate website at:

End of ad hoc

end of announcement                                euro adhoc 23.05.2005 15:16:33

Further inquiry note: Dr. Erwin Amashaufer, curasan AG, Tel. 06027/46 86 0, email:

Branche: Biotechnology
ISIN:      DE0005494538
WKN:        549453
Index:    CDAX, Classic All Share, Prime Standard, Prime All Share
Börsen:  Frankfurter Wertpapierbörse / regulated dealing
              Berliner Wertpapierbörse / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Niedersächsische Börse zu Hannover / free trade
              Bayerische Börse / free trade
              Bremer Wertpapierbörse (BWB) / free trade

Original content of: Curasan AG, transmitted by news aktuell

All Releases
Subscribe to Curasan AG
  • Printable version
  • PDF version

Topics in this relase